NPCE
NeuroPace, Inc. [NPCE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NPCE Stock Summary
In the News
NeuroPace, Inc. (NPCE) CEO Michael Favet on Q1 2023 Results - Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President & Chief Executive Officer, NeuroPace, Inc. Rebecca Kuhn - Chief Financial Officer & Vice President, NeuroPace, Inc. Conference Call Participants Rohan - JP Morgan Frank Takkinen - Lake Street Capital Markets Michael Polark - Wolfe Research Operator Good afternoon, and welcome to NeuroPace's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023
MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.
NeuroPace, Inc. (NPCE) Q4 2022 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2022 Results Conference Call March 2, 2023 4:30 PM ET Company Participants Trip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Michael Polark - Wolfe Research Frank Takkinen - Lake Street Capital Markets Robbie Marcus - JPMorgan Vik Chopra - Wells Fargo Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to NeuroPace's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
MOUNTAIN VIEW, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 2, 2023. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results
Fintel reports that Accelmed Partners II L.P.
Neuropace, Inc. (NPCE) Q3 2022 Earnings Call Transcript
Neuropace, Inc. (NASDAQ:NPCE ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Michael Favet - President, CEO & Director Rebecca Kuhn - CFO, VP, Finance & Administration and Assistant Secretary Conference Call Participants Allen Gong - JPMorgan Chase & Co. Lawrence Biegelsen - Wells Fargo Securities Operator Good day, and thank you for standing by. Welcome to the Q3 2022 NeuroPace earnings conference call.
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 4th Annual Wolfe Research Healthcare Conference. Management is scheduled to present on Wednesday, November 16th at 2:40 p.m. Eastern Time. A live webcast of this event, as well as an archived recording, will be available on the “Investors” section of the company's website at: https://investors.neuropace.com. The webcasts will be archived and available for replay for at least 90 days after the event.
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
MOUNTAIN VIEW, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter 2022 after market close on Tuesday, November 8, 2022. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time.
NPCE Financial details
NPCE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 3.33 | 3.71 | 2.72 | 1.85 | |
| Net income per share | -3.41 | -3.2 | -2.92 | -2.17 | |
| Operating cash flow per share | -2.25 | -1.95 | -1.48 | -1.5 | |
| Free cash flow per share | -2.3 | -1.95 | -1.5 | -1.52 | |
| Cash per share | 0.46 | 3.43 | 6.96 | 3.15 | |
| Book value per share | -11.65 | -13.31 | 4.43 | 1.41 | |
| Tangible book value per share | -11.65 | -13.31 | 4.43 | 1.41 | |
| Share holders equity per share | -11.65 | -13.31 | 4.43 | 1.41 | |
| Interest debt per share | 6.51 | 5.8 | 3.45 | 3.14 | |
| Market cap | 277.14M | 277.14M | 167.42M | 36.65M | |
| Enterprise value | 335.82M | 303.61M | 198.08M | 99.81M | |
| P/E ratio | -7.31 | -7.81 | -3.46 | -0.69 | |
| Price to sales ratio | 7.5 | 6.74 | 3.71 | 0.81 | |
| POCF ratio | -11.07 | -12.83 | -6.81 | -0.99 | |
| PFCF ratio | -10.87 | -12.79 | -6.71 | -0.98 | |
| P/B Ratio | -2.14 | -1.87 | 2.28 | 1.05 | |
| PTB ratio | -2.14 | -1.87 | 2.28 | 1.05 | |
| EV to sales | 9.08 | 7.38 | 4.38 | 2.19 | |
| Enterprise value over EBITDA | -16.73 | -24.33 | -6.98 | -2.52 | |
| EV to operating cash flow | -13.42 | -14.05 | -8.06 | -2.71 | |
| EV to free cash flow | -13.17 | -14.01 | -7.94 | -2.66 | |
| Earnings yield | -0.14 | -0.13 | -0.29 | -1.46 | |
| Free cash flow yield | -0.09 | -0.08 | -0.15 | -1.02 | |
| Debt to equity | -1.16 | -1.38 | 0.82 | 2.28 | |
| Debt to assets | 7.13 | 3.64 | 0.45 | 0.7 | |
| Net debt to EBITDA | -2.92 | -2.12 | -1.08 | -1.6 | |
| Current ratio | 0.27 | 5.69 | 14.28 | 8.9 | |
| Interest coverage | -2.32 | -1.14 | -3.2 | -5.42 | |
| Income quality | 0.83 | 0.89 | 0.68 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.49 | 0.38 | 0.4 | 0.48 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0 | 0.02 | 0.02 | |
| Capex to revenue | -0.01 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -1.11 | -0.2 | -1.3 | -0.2 | |
| Stock based compensation to revenue | 0.04 | 0.03 | 0.09 | 0.18 | |
| Graham number | 29.92 | 30.95 | 17.04 | 8.31 | |
| ROIC | -2.33 | -8.59 | -0.34 | -0.47 | |
| Return on tangible assets | -1.8 | -0.63 | -0.36 | -0.47 | |
| Graham Net | -12.33 | -14.05 | 3.9 | 0.35 | |
| Working capital | -54.89M | 44.97M | 123.52M | 86.74M | |
| Tangible asset value | -129.35M | -147.83M | 73.5M | 34.78M | |
| Net current asset value | -130.19M | -149.22M | 72.76M | 18.39M | |
| Invested capital | -0.49 | -0.36 | 0.68 | 2.01 | |
| Average receivables | 0 | 7.21M | 7.74M | 7.29M | |
| Average payables | 0 | 926K | 1.16M | 1.76M | |
| Average inventory | 0 | 7.4M | 7.37M | 8.77M | |
| Days sales outstanding | 59.4 | 74.49 | 57.28 | 59.99 | |
| Days payables outstanding | 31.37 | 31.88 | 42.81 | 60.16 | |
| Days of inventory on hand | 274.41 | 232.08 | 243.02 | 272.12 | |
| Receivables turnover | 6.14 | 4.9 | 6.37 | 6.08 | |
| Payables turnover | 11.64 | 11.45 | 8.53 | 6.07 | |
| Inventory turnover | 1.33 | 1.57 | 1.5 | 1.34 | |
| ROE | 0.29 | 0.24 | -0.66 | -1.53 | |
| Capex per share | -0.04 | -0.01 | -0.02 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.47 | 0.42 | 0.45 | 0.51 | 0.58 | |
| Net income per share | -0.54 | -0.59 | -0.54 | -0.5 | -0.57 | |
| Operating cash flow per share | -0.47 | -0.43 | -0.28 | -0.32 | -0.39 | |
| Free cash flow per share | -0.48 | -0.44 | -0.28 | -0.32 | -0.39 | |
| Cash per share | 4.24 | 3.77 | 3.45 | 3.12 | 2.69 | |
| Book value per share | 2.58 | 2.16 | 1.76 | 1.4 | 1.1 | |
| Tangible book value per share | 2.58 | 2.16 | 1.76 | 1.4 | 1.1 | |
| Share holders equity per share | 2.58 | 2.16 | 1.76 | 1.4 | 1.1 | |
| Interest debt per share | 2.42 | 2.41 | 2.84 | 2.89 | 2.88 | |
| Market cap | 199.56M | 121.29M | 92.73M | 37M | 116.45M | |
| Enterprise value | 249.05M | 172.77M | 155.38M | 100.16M | 180.1M | |
| P/E ratio | -3.79 | -2.1 | -1.73 | -0.74 | -2.02 | |
| Price to sales ratio | 17.55 | 11.89 | 8.31 | 2.89 | 8.05 | |
| POCF ratio | -17.52 | -11.38 | -13.3 | -4.72 | -12.01 | |
| PFCF ratio | -17.06 | -11.21 | -13.24 | -4.66 | -11.85 | |
| P/B Ratio | 3.18 | 2.29 | 2.14 | 1.06 | 4.24 | |
| PTB ratio | 3.18 | 2.29 | 2.14 | 1.06 | 4.24 | |
| EV to sales | 21.9 | 16.94 | 13.93 | 7.83 | 12.44 | |
| Enterprise value over EBITDA | -28.05 | -17.12 | -17 | -10.88 | -22.47 | |
| EV to operating cash flow | -21.86 | -16.21 | -22.28 | -12.77 | -18.57 | |
| EV to free cash flow | -21.29 | -15.96 | -22.18 | -12.61 | -18.32 | |
| Earnings yield | -0.07 | -0.12 | -0.14 | -0.34 | -0.12 | |
| Free cash flow yield | -0.06 | -0.09 | -0.08 | -0.21 | -0.08 | |
| Debt to equity | 1.05 | 1.24 | 1.78 | 2.28 | 2.87 | |
| Debt to assets | 0.51 | 0.55 | 0.64 | 0.7 | 0.74 | |
| Net debt to EBITDA | -5.57 | -5.1 | -6.85 | -6.86 | -7.94 | |
| Current ratio | 10.15 | 9.86 | 11.08 | 8.9 | 9.13 | |
| Interest coverage | -5.33 | -5.93 | -5.35 | -5.08 | -4.23 | |
| Income quality | 0.99 | 0.84 | 0.59 | 0.7 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.49 | 0.56 | 0.5 | 0.4 | 0.36 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.02 | 0 | 0.01 | 0.01 | |
| Capex to revenue | -0.03 | -0.02 | 0 | -0.01 | -0.01 | |
| Capex to depreciation | -0.41 | -0.22 | -0.04 | -0.14 | -0.33 | |
| Stock based compensation to revenue | 0.13 | 0.26 | 0.2 | 0.16 | 0.15 | |
| Graham number | 5.61 | 5.34 | 4.62 | 3.97 | 3.76 | |
| ROIC | -0.1 | -0.12 | -0.11 | -0.11 | -0.13 | |
| Return on tangible assets | -0.1 | -0.12 | -0.11 | -0.11 | -0.14 | |
| Graham Net | 1.97 | 1.52 | 0.75 | 0.34 | 0.04 | |
| Working capital | 110.36M | 101.06M | 94.95M | 86.74M | 80.28M | |
| Tangible asset value | 62.82M | 52.9M | 43.41M | 34.78M | 27.49M | |
| Net current asset value | 56.26M | 46.82M | 27.31M | 18.39M | 11.38M | |
| Invested capital | 0.91 | 1.08 | 1.57 | 2.01 | 2.56 | |
| Average receivables | 8.08M | 8.77M | 8.18M | 7.68M | 8.34M | |
| Average payables | 1.11M | 1.87M | 1.34M | 1.66M | 1.99M | |
| Average inventory | 7.96M | 8.26M | 8.5M | 9.15M | 10.23M | |
| Days sales outstanding | 71.7 | 74.77 | 63.53 | 52.65 | 57.18 | |
| Days payables outstanding | 64.37 | 49.48 | 33.13 | 48.48 | 40.15 | |
| Days of inventory on hand | 234.12 | 277.14 | 241.95 | 219.29 | 235.98 | |
| Receivables turnover | 1.26 | 1.2 | 1.42 | 1.71 | 1.57 | |
| Payables turnover | 1.4 | 1.82 | 2.72 | 1.86 | 2.24 | |
| Inventory turnover | 0.38 | 0.32 | 0.37 | 0.41 | 0.38 | |
| ROE | -0.21 | -0.27 | -0.31 | -0.36 | -0.52 | |
| Capex per share | -0.01 | -0.01 | 0 | 0 | -0.01 |
NPCE Frequently Asked Questions
What is NeuroPace, Inc. stock symbol ?
NeuroPace, Inc. is a US stock , located in Mountain view of Ca and trading under the symbol NPCE
Is NeuroPace, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $5.75. The lowest prediction is $5.5 and the highest is $6
What is NPCE stock prediction ?
What is NeuroPace, Inc. stock quote today ?
NeuroPace, Inc. stock price is $4.42 today.
Is NeuroPace, Inc. stock public?
Yes, NeuroPace, Inc. is a publicly traded company.
Company Profile
- Volume Average 22.19K
- Market Capitalization 114.32M
- Employee 163
- CEO Mr. Michael L. Favet
- Headquarters Mountain View,CA,US
- IPO Date 2021-04-21
-
Website
https://www.neuropace.com 
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
